MCID: DBT010
MIFTS: 55

Diabetic Neuropathy

Categories: Blood diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Diabetic Neuropathy

MalaCards integrated aliases for Diabetic Neuropathy:

Name: Diabetic Neuropathy 12 74 53 36 15 37 17
Diabetic Neuropathies 54 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9743
KEGG 36 H01459
ICD9CM 34 250.6
MeSH 43 D003929
NCIt 49 C26748
SNOMED-CT 67 866003
UMLS 71 C0011882

Summaries for Diabetic Neuropathy

NINDS : 53 Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.

MalaCards based summary : Diabetic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and diabetic autonomic neuropathy, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Neuropathy is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and PI3K-Akt signaling pathway. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and spinal cord, and related phenotypes are behavior/neurological and growth/size/body region

KEGG : 36 Diabetic neuropathies (DNs) are nerve damaging disorders caused by diabetes. Diabetic neuropathy broadly comprise generalized symmetric polyneuropathies (acute sensory, chronic sensorimotor, autonomic) and asymmetric (focal and multifocal) neuropathies (cranial, truncal, focal-limb, proximal-motor, coexisting chronic inflammatory demyelinating), which affect all organs and system. Of all types, diabetic sensorimotor polyneuropathy (DSPN), also called distal symmetric neuropathy, is the most typical form. Typical Symptoms vary from person to person, but may include numbness, tingling, pain, or weakness that typically starts in the feet and progresses up the legs. This pattern of neuropathy shows a progressive distal axonopathy. It has been reported that vascular endothelial growth factor A is associated with DNs development and progression.

Wikipedia : 74 Diabetic neuropathies consist of various types of nerve damage associated with diabetes mellitus.... more...

Related Diseases for Diabetic Neuropathy

Diseases related to Diabetic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 33.5 VEGFA NTF3 NGF INS AKR1B1 AGER
2 diabetic autonomic neuropathy 33.1 NTF3 NGF INS EPO AKR1B1 ACE
3 microvascular complications of diabetes 3 32.9 INS AKR1B1 AGER ACE
4 diabetes mellitus, insulin-dependent 32.6 VEGFA SOD2 LEP INS AKR1B1 ACE
5 microvascular complications of diabetes 5 32.5 VEGFA SORD SOD2 INS AKR1B1 AGER
6 diabetes mellitus, noninsulin-dependent 32.3 VEGFA NGF LEP INS AKR1B1 AGER
7 neuropathy 31.9 VEGFA SCN9A PMP22 NTRK1 NGF MPZ
8 hyperglycemia 31.5 SORD SOD2 LEP INS AKR1B1 AGER
9 diabetic polyneuropathy 31.4 VEGFA SOD2 NTF3 NGF INS AKR1B1
10 autonomic neuropathy 31.2 SCN9A NTRK1 NTF3 NGF INS EPO
11 mononeuropathy 31.1 TRPV1 PMP22 NGF MPZ
12 peripheral vascular disease 31.0 VEGFA SCN9A INS EPO ACE
13 vascular disease 30.9 VEGFA LEP INS EPO AGER ACE
14 polyneuropathy 30.9 VEGFA PMP22 NGF MPZ INS GDNF
15 neuritis 30.9 PMP22 MPZ GDNF
16 carpal tunnel syndrome 30.7 VEGFA PMP22 MPZ INS ACE
17 sensory peripheral neuropathy 30.7 TRPV1 PMP22 NTRK1 NTF3 NGF MPZ
18 sleep apnea 30.5 VEGFA LEP INS EPO ACE
19 uremia 30.5 LEP INS EPO ACE
20 prediabetes syndrome 30.5 LEP INS ACE
21 diabetic angiopathy 30.5 SOD2 INS AGER
22 diabetic encephalopathy 30.5 NGF INS GDNF
23 diabetes mellitus 30.4 VEGFA SORD SOD2 LEP INS EPO
24 sleep disorder 30.4 LEP INS ACE
25 constipation 30.4 OPRD1 NTF3 GDNF CALCA AKR1B1
26 neurogenic arthropathy 30.4 SCN9A NGF INS CALCA
27 complex regional pain syndrome 30.4 SCN9A CALCA ACE
28 silent myocardial infarction 30.3 INS ACE
29 bone resorption disease 30.3 LEP INS CALCA
30 burning mouth syndrome 30.3 TRPV1 SCN9A NGF CALCA
31 algoneurodystrophy 30.3 NGF INS CALCA
32 cerebrovascular disease 30.2 LEP INS AGER ACE
33 apnea, obstructive sleep 30.2 VEGFA LEP INS ACE
34 pain agnosia 30.2 TRPV1 TRPM8 SCN9A OPRD1 NGF CALCA
35 fibromyalgia 30.2 SCN9A OPRD1 NGF LEP INS CALCA
36 congestive heart failure 30.2 VEGFA INS EPO ACE
37 ischemia 30.2 VEGFA SOD2 EPO ACE
38 motor neuron disease 30.1 VEGFA SOD2 NTF3 INS GDNF
39 arteries, anomalies of 30.1 VEGFA LEP INS ACE
40 cataract 30.1 VEGFA SORD SOD2 LEP INS AKR1B1
41 uremic neuropathy 30.0 PMP22 EPO
42 atherosclerosis susceptibility 30.0 VEGFA LEP INS AGER ACE
43 peripheral nervous system disease 30.0 VEGFA TRPV1 TRPM8 SCN9A PMP22 NTRK1
44 demyelinating disease 30.0 PMP22 NTF3 NGF MPZ
45 kidney disease 29.9 VEGFA LEP INS EPO AKR1B1 AGER
46 trigeminal neuralgia 29.9 TRPV1 SCN9A OPRD1 CALCA
47 myocardial infarction 29.9 VEGFA LEP INS EPO AGER ACE
48 neuroblastoma 29.8 VEGFA SOD2 NTRK1 NTF3 NGF INS
49 charcot-marie-tooth disease 29.7 SCN9A PMP22 NTRK1 NTF3 NGF MPZ
50 body mass index quantitative trait locus 11 29.6 VEGFA TRPV1 SOD2 LEP INS AKR1B1

Graphical network of the top 20 diseases related to Diabetic Neuropathy:



Diseases related to Diabetic Neuropathy

Symptoms & Phenotypes for Diabetic Neuropathy

UMLS symptoms related to Diabetic Neuropathy:


sciatica, neuralgia

MGI Mouse Phenotypes related to Diabetic Neuropathy:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 ACE AGER AKR1B1 GDNF INS LEP
2 growth/size/body region MP:0005378 10.39 ACE AGER AKR1B1 GDNF INS LEP
3 homeostasis/metabolism MP:0005376 10.37 ACE AGER AKR1B1 EPO INS LEP
4 integument MP:0010771 10.27 AGER EPO INS LEP MPZ NGF
5 cardiovascular system MP:0005385 10.26 ACE AGER EPO GDNF INS LEP
6 immune system MP:0005387 10.26 ACE AGER EPO GDNF INS LEP
7 mortality/aging MP:0010768 10.25 ACE AKR1B1 EPO GDNF INS LEP
8 nervous system MP:0003631 10.17 GDNF INS LEP MPZ NGF NTF3
9 muscle MP:0005369 10.11 AGER EPO GDNF INS LEP NGF
10 liver/biliary system MP:0005370 9.98 ACE EPO INS LEP SOD2 TRPV1
11 normal MP:0002873 9.91 AGER EPO INS NGF NTF3 NTRK1
12 renal/urinary system MP:0005367 9.85 ACE AGER AKR1B1 GDNF INS LEP
13 reproductive system MP:0005389 9.61 ACE GDNF INS LEP MPZ NTF3
14 vision/eye MP:0005391 9.32 AKR1B1 INS LEP NGF NTF3 NTRK1

Drugs & Therapeutics for Diabetic Neuropathy

Drugs for Diabetic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 322)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
4
Histamine Approved, Investigational Phase 4 51-45-6 774
5
Amitriptyline Approved Phase 4 50-48-6 2160
6
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
9
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
10
leucovorin Approved Phase 4 58-05-9 6006 143
11
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
12
Cetirizine Approved Phase 4 83881-51-0 2678
13
Metformin Approved Phase 4 657-24-9 4091 14219
14
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
15
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
16
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
19
Linaclotide Approved Phase 4 851199-59-2 65351
20
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
21
Donepezil Approved Phase 4 120014-06-4 3152
22
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
23
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
26
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
27
Cobalamin Experimental Phase 4 13408-78-1 6857388
28 Chelating Agents Phase 4
29 Benphothiamine Phase 4
30 Adjuvants, Immunologic Phase 4
31 Angiotensinogen Phase 4
32 Giapreza Phase 4
33 Alpha-lipoic Acid Phase 4
34 Thioctic Acid Phase 4
35 Histamine Antagonists Phase 4
36 Histamine H1 Antagonists Phase 4
37 Anti-Allergic Agents Phase 4
38
Histamine Phosphate Phase 4 51-74-1 65513
39 Amitriptyline, perphenazine drug combination Phase 4
40 Hypolipidemic Agents Phase 4
41 Evening Primrose Phase 4
42 Antimetabolites Phase 4
43 Linoleate Phase 4
44 Lipid Regulating Agents Phase 4
45 Vitamin B 12 Phase 4
46 Vitamin B12 Phase 4
47 Citrate Phase 4
48 Sildenafil Citrate Phase 4 171599-83-0
49 Phosphodiesterase 5 Inhibitors Phase 4
50 Phosphodiesterase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 505)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
2 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
3 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
4 Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery Unknown status NCT02535000 Phase 4 Duloxetine;Placebo
5 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
6 Effects of Pregabalin on Mechanical Hyperalgesia - EPOM Unknown status NCT00310583 Phase 4 Pregabalin
7 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
8 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
9 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
10 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
11 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
12 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
13 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
14 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
15 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
16 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
17 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
18 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
19 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
20 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
21 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
22 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
23 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
24 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
25 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
26 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
27 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
28 A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
29 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
30 PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS Completed NCT02249897 Phase 4 CHOLESTYRAMINE
31 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
32 A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers Completed NCT01835379 Phase 4
33 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
34 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
35 A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases Completed NCT01352767 Phase 4
36 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
37 Open Labelled Study of Pregabalin in the Treatment of Neuropathic Pain in Cervical Myeloradiculopathy (Pregabalin and Radicular Pain Study (PARPS)) Completed NCT01061697 Phase 4 Pregabalin
38 Efficacy of Pregabalin in Patients With Radicular Pain Completed NCT00908375 Phase 4 Pregabalin;Sugar Pill
39 A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy. Completed NCT00903851 Phase 4 Lidoderm
40 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
41 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
42 Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain. Completed NCT03047278 Phase 4 Gabapentin 300 mg;Cetirizine Hydrochloride 10 mg
43 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
44 Dipeptidyl Peptidase (DPP) IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Patients With Type 2 Diabetes Completed NCT01472432 Phase 4 Placebo;vildagliptin
45 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
46 L-Arginine and Endothelial Dysfunction in Type 2 Diabetic Patients Completed NCT00902616 Phase 4
47 The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
48 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
49 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
50 Comparison of Analgesic Effects of Gabapentin and Paracetamol in Patients With Hand Injury Recruiting NCT04068506 Phase 4 Gabapentin 600 mg Tab

Search NIH Clinical Center for Diabetic Neuropathy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Becaplermin
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
Citalopram
Citalopram hydrobromide
COBALAMIN CONCENTRATE
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
mecobalamin
Mexiletine
Mexiletine Hydrochloride
Pentoxifylline
Vitamin B 12

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetic Neuropathy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Diabetic Neuropathy:
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
Embryonic/Adult Cultured Cells Related to Diabetic Neuropathy:
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for Diabetic Neuropathy

Anatomical Context for Diabetic Neuropathy

MalaCards organs/tissues related to Diabetic Neuropathy:

40
Testes, Skin, Spinal Cord, Endothelial, Heart, Bone, Brain

Publications for Diabetic Neuropathy

Articles related to Diabetic Neuropathy:

(show top 50) (show all 6574)
# Title Authors PMID Year
1
Cav-1 participates in the development of diabetic neuropathy pain through the TLR4 signaling pathway. 61
31318049 2020
2
LONP1 induction by SRT1720 attenuates mitochondrial dysfunction against high glucose induced neurotoxicity in PC12 cells. 61
31639451 2020
3
Intraepidermal Nerve Fiber Analysis in Human Patients and Animal Models of Peripheral Neuropathy: A Comparative Review. 61
31221022 2020
4
Patient-reported improvement in pain with pregabalin for painful diabetic neuropathy and postherpetic neuralgia is promising but needs further investigation. 61
31092541 2020
5
Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats. 61
31794708 2020
6
A study protocol on nerve mobilization induced diffusion tensor imaging values in posterior tibial nerve in healthy controls and in patients with diabetic neuropathy-multigroup pretest posttest design. 61
31650071 2019
7
Acupuncture for painful diabetic neuropathy. 61
31433572 2019
8
Polyphenols for diabetes associated neuropathy: Pharmacological targets and clinical perspective. 61
31352568 2019
9
Effects of adipose derived stromal vascular fraction on diabetic neuropathy: an experimental study. 61
31240978 2019
10
Augmented Corneal Nerve Fiber Branching in Painful Compared With Painless Diabetic Neuropathy. 61
31390004 2019
11
Overexpression of Sirtuin 1 protein in neurons prevents and reverses experimental diabetic neuropathy. 61
31754701 2019
12
Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis? 61
31826273 2019
13
The Association Between Phosphorylated Neurofilament Heavy Chain (pNF-H) and Small Fiber Neuropathy (SFN) in Patients with Impaired Glucose Tolerance. 61
31673971 2019
14
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. 61
31853709 2019
15
Anxiety, depression and sleep disorders in patients with diabetic neuropathic pain: a systematic review. 61
31393191 2019
16
Farrerol alleviates high glucose-induced renal mesangial cell injury through the ROS/Nox4/ERK1/2 pathway. 61
31838053 2019
17
Insulin Resistance in Type 1 Diabetes Mellitus and Its Association with Patient's Micro- and Macrovascular Complications, Sex Hormones, and Other Clinical Data. 61
31792784 2019
18
Diabetic neuropathy: A focus on small fibres. 61
31828951 2019
19
Diabetes mellitus alters electrophysiological properties in neurons of superior cervical ganglion of rats. 61
31843626 2019
20
Psychosocial research in the diabetic foot: Are we making progress? 61
31850665 2019
21
Understanding Diabetic Neuropathy: From Subclinical Nerve Lesions to Severe Nerve Fiber Deficits. A Cross-Sectional Study in Patients with Type 2 Diabetes and Healthy Controls. 61
31826867 2019
22
Activation of Kv7 channels with the anticonvulsant retigabine alleviates neuropathic pain behaviour in the streptozotocin rat model of diabetic neuropathy. 61
30995134 2019
23
Relationship between diabetic neuropathy and sarcopenia. 61
31126745 2019
24
Diabetic neuropathy research: from mouse models to targets for treatment. 61
31290436 2019
25
Glycolaldehyde induces sensory neuron death through activation of the c-Jun N-terminal kinase and p-38 MAP kinase pathways. 61
31734714 2019
26
γ-Linolenic Acid versus α-Lipoic Acid for Treating Painful Diabetic Neuropathy in Adults: A 12-Week, Double-Placebo, Randomized, Noninferiority Trial. 61
31701699 2019
27
Prevalence and risk factors for painful diabetic neuropathy in secondary healthcare in Qatar. 61
30860314 2019
28
Disrupting insulin signaling in Schwann cells impairs myelination and induces a sensory neuropathy. 61
31758725 2019
29
Predictive model to identify the risk of losing protective sensibility of the foot in patients with diabetes mellitus. 61
31691513 2019
30
Nonhealing Wounds with Verrucous Presentation in the Neuropathic Patient: A Report of Two Cases. 61
31755775 2019
31
Protective effects of hydrogen‑rich saline against experimental diabetic peripheral neuropathy via activation of the mitochondrial ATP‑sensitive potassium channel channels in rats. 61
31746358 2019
32
Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy. 61
31720872 2019
33
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. 61
31728713 2019
34
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG. 61
31636082 2019
35
Clinical and epidemiological differences in diabetes: A cross-sectional study of the Brazilian population compared with the French GERODIAB cohort. 61
31778744 2019
36
Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran. 61
31701435 2019
37
Lumos for the long trail: Strategies for clinical diagnosis and severity staging for diabetic polyneuropathy and future directions. 61
31677343 2019
38
Clinical efficacy and tolerability of Gabapentinoids with current prescription patterns in patients with Neuropathic pain. 61
31777483 2019
39
Significant polar vasculosis in a patient with a 30-year history of type 2 diabetes. 61
31743098 2019
40
Methylglyoxal causes pain and hyperalgesia in human through C-fiber activation. 61
31219946 2019
41
Raman spectroscopy of dorsal root ganglia from streptozotocin-induced diabetic neuropathic rats submitted to photobiomodulation therapy. 61
31265175 2019
42
A new prospective on the role of melatonin in diabetes and its complications. 61
31693492 2019
43
Streptozotocin-Induced Diabetic Neuropathic Pain Is Associated with Potentiated Calcium-Permeable AMPA Receptor Activity in the Spinal Cord. 61
31481518 2019
44
Ginger extract and its compound, 6-shogaol, attenuates painful diabetic neuropathy in mice via reducing TRPV1 and NMDAR2B expressions in the spinal cord. 61
31743763 2019
45
An artificial intelligence-based deep learning algorithm for the diagnosis of diabetic neuropathy using corneal confocal microscopy: a development and validation study. 61
31720728 2019
46
Overwhelming Need, Insufficient Health Care for Justice-involved North Carolinians. 61
31685566 2019
47
Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy. 61
31338868 2019
48
Genetics of diabetic neuropathy: Systematic review, meta-analysis and trial sequential analysis. 61
31557408 2019
49
Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease? 61
31145897 2019
50
The preventive effect of IL-1beta antagonist on Diabetic Peripheral Neuropathy. 61
31642797 2019

Variations for Diabetic Neuropathy

Expression for Diabetic Neuropathy

Search GEO for disease gene expression data for Diabetic Neuropathy.

Pathways for Diabetic Neuropathy

Pathways related to Diabetic Neuropathy according to KEGG:

36
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933

GO Terms for Diabetic Neuropathy

Cellular components related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 VEGFA NTF3 NGF LEP INS GDNF
2 extracellular space GO:0005615 9.36 VEGFA SORD NTF3 NGF LEP INS

Biological processes related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10 VEGFA NTF3 LEP INS GDNF EPO
2 positive regulation of cell migration GO:0030335 9.91 VEGFA SOD2 NTF3 INS
3 response to hypoxia GO:0001666 9.87 VEGFA LEP EPO AGER
4 positive regulation of cold-induced thermogenesis GO:0120162 9.82 VEGFA TRPM8 LEP
5 activation of protein kinase activity GO:0032147 9.81 VEGFA EPO CALCA
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.8 VEGFA OPRD1 NTF3
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 VEGFA LEP EPO
8 cellular response to growth factor stimulus GO:0071363 9.77 TRPV1 OPRD1 NTRK1
9 glucose metabolic process GO:0006006 9.77 SORD LEP INS
10 response to nutrient levels GO:0031667 9.76 SORD NTRK1 LEP
11 sensory perception of pain GO:0019233 9.75 TRPV1 SCN9A NTRK1
12 cellular response to nerve growth factor stimulus GO:1990090 9.71 TRPV1 NTRK1 CALCA
13 positive regulation of p38MAPK cascade GO:1900745 9.67 VEGFA LEP AGER
14 regulation of blood pressure GO:0008217 9.67 SOD2 LEP CALCA ACE
15 positive regulation of Ras protein signal transduction GO:0046579 9.65 NTRK1 NGF EPO
16 negative regulation of neuron apoptotic process GO:0043524 9.65 SOD2 NTRK1 NTF3 NGF GDNF
17 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.63 SOD2 INS
18 behavioral response to pain GO:0048266 9.63 TRPV1 SCN9A
19 commissural neuron axon guidance GO:0071679 9.62 VEGFA GDNF
20 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.61 TRPV1 NTRK1 CALCA
21 induction of positive chemotaxis GO:0050930 9.58 VEGFA NTF3 AGER
22 negative regulation of calcium ion transport into cytosol GO:0010523 9.56 EPO CALCA
23 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.55 VEGFA ACE
24 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.55 NTRK1 NTF3 LEP INS EPO
25 thermoception GO:0050955 9.51 TRPV1 TRPM8
26 nerve growth factor signaling pathway GO:0038180 9.5 NTRK1 NTF3 NGF
27 fructose biosynthetic process GO:0046370 9.46 SORD AKR1B1
28 peripheral nervous system development GO:0007422 9.26 PMP22 NTF3 NGF GDNF
29 negative regulation of apoptotic process GO:0043066 9.23 VEGFA NTRK1 NGF MPZ LEP GDNF

Molecular functions related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.65 NTF3 NGF LEP GDNF CALCA
2 growth factor activity GO:0008083 9.46 VEGFA NTF3 NGF GDNF
3 identical protein binding GO:0042802 9.28 VEGFA TRPV1 TRPM8 SORD SOD2 NTRK1
4 hormone activity GO:0005179 9.26 LEP INS EPO CALCA

Sources for Diabetic Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....